PBR Nachrichten

 

This territory includes Hong Kong, Macau, Mainland China, and Taiwan. The focus of the partnership is to address the needs of more than 90 million people affected by The post Aligos and Xiamen Amoytop sign deal for HBV therapy appeared first on Pharmaceutical Business review....

The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna's MNM technology as a delivery enhancer for therapeutic modalities. Interna's MNM molecules The post Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions appeared first on Pharmaceutical Business review....

The collaboration aims to bridge gaps between data generation and actionable insights in spatial proteomics, as multiplex technologies for imaging advance. Spatial proteomics platforms create intricate tissue data, The post Nucleai and Sirona Dx to provide new proteomics solution for pharma companies appeared first on Pharmaceutical Business review....

This Phase Ib/II study will measure the tolerability, safety, and early clinical activity by combining Boehringer Ingelheim's DLL3 / cluster of differentiation 3 (CD3) T-cell engager, obrixtamig, with The post Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study appeared first on Pharmaceutical Business review....

The financing will support Adcendo's ongoing advancement of its first-in-class and best-in-class ADC pipeline targeting cancers of high unmet medical need, including further clinical development of three main The post Adcendo secures $75m in Series C funding for ADC development appeared first on Pharmaceutical Business review....

The acquisition includes the lead candidate CBB-120, a dual-payload antibody-drug conjugate (ADC) developed to treat cancer. The therapy is anticipated to have a US Food and Drug Administration The post Lilly to acquire CrossBridge Bio for up to $300m appeared first on Pharmaceutical Business review....

The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. FSGS is The post Travere Therapeutics gains FDA approval for sparsentan in FSGS appeared first on Pharmaceutical Business review....

The treatment targets adult patients with ES-SCLC who have experienced disease progression on or after platinum-based chemotherapy. The FDA has scheduled a decision date for 10 October 2026 The post MSD, Daiichi Sankyo's ifinatamab deruxtecan receives FDA priority appeared first on Pharmaceutical Business review....

Telix and Regeneron Pharmaceuticals have entered a partnership for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical platforms, global The post Telix and Regeneron to co-develop radiopharmaceutical therapies appeared first on Pharmaceutical Business review....

The decision affects Replimune's lead product candidate, which is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response. During the IGNYTE trial, The post FDA issues complete response letter to Replimune's RP1 for melanoma appeared first on Pharmaceutical Business review....

According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets. C4 Therapeutics will use its TORPEDO platform for The post Roche and C4 Therapeutics to advance degrader-antibody conjugates research appeared first on Pharmaceutical Business review....

Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan & Lee. Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise the The post Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation appeared first on Pharmaceutical Business review....

The acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets. Under the deal, Everest Medicines will pay a total consideration of $250m in The post EverSea Medicines to acquire Hasten Biopharmaceuticals appeared first on Pharmaceutical Business review....

The milestone increases Jeito's assets under management to €1.6bn, following the €534m closure of Jeito I in 2021. Continuing the initiative set by Jeito I, Jeito II will The post Jeito Capital secures over $1.2bn for new biopharma investments appeared first on Pharmaceutical Business review....

MineBio will supply RoosterBio's complete platform of products, having already obtained import clearance. This facilitates prompt fulfilment of orders for both research and clinical-grade media solutions focused on The post RoosterBio and MineBio team up to expand MSC solutions access in China appeared first on Pharmaceutical Business review....

Vertex has licensed the technology for use in up to three drug targets, as part of the agreement. The Hypercon microparticle platform enables hyperconcentration of drugs and biologics, The post Halozyme and Vertex sign deal for Hypercon technology appeared first on Pharmaceutical Business review....

The funding will be used for commercial readiness and the potential US launch of the company's lead product candidate, AD109, pending approval by the US Food and Drug The post Apnimed obtains up to $150m in funds for commercial launch of AD109 appeared first on Pharmaceutical Business review....

The transaction will expand Neurocrine's portfolio in endocrinology and rare diseases via the addition of Soleno's lead product, Vykat XR (diazoxide choline), for Prader-Willi syndrome (PWS). Vykat XR The post Neurocrine to acquire Soleno in $2.9bn transaction appeared first on Pharmaceutical Business review....

The project will enhance Aspect Biosystems' clinical development capabilities and bolster its integrated platform for developing and manufacturing advanced cellular medicines. The investment is in addition to the The post Aspect Biosystems receives funding for cellular medicine project appeared first on Pharmaceutical Business review....

The approval in the European Union (EU) is for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours are PD-L1 positive, with a combined The post MSD secures EC clearance for Keytruda combination therapy for ovarian cancer appeared first on Pharmaceutical Business review....